IL150150A0 - 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation - Google Patents

1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation

Info

Publication number
IL150150A0
IL150150A0 IL15015001A IL15015001A IL150150A0 IL 150150 A0 IL150150 A0 IL 150150A0 IL 15015001 A IL15015001 A IL 15015001A IL 15015001 A IL15015001 A IL 15015001A IL 150150 A0 IL150150 A0 IL 150150A0
Authority
IL
Israel
Prior art keywords
microglia activation
illnesses associated
treating illnesses
benzimidazoles
diaryl
Prior art date
Application number
IL15015001A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL150150A0 publication Critical patent/IL150150A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
IL15015001A 2000-01-14 2001-01-12 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation IL150150A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10002898 2000-01-14
PCT/EP2001/000334 WO2001051473A1 (de) 2000-01-14 2001-01-12 1,2-diarylbenzimidazole zur behandlung von krankungen die mit einer microglia-aktivierung assoziiert sind

Publications (1)

Publication Number Publication Date
IL150150A0 true IL150150A0 (en) 2002-12-01

Family

ID=7628535

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15015001A IL150150A0 (en) 2000-01-14 2001-01-12 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
IL150150A IL150150A (en) 2000-01-14 2002-06-11 Use of 1,2-diaryl benzimidazoles for the preparation of pharmaceutical preparations for the treatment of diseases related to microglia activation and a number of such new compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150150A IL150150A (en) 2000-01-14 2002-06-11 Use of 1,2-diaryl benzimidazoles for the preparation of pharmaceutical preparations for the treatment of diseases related to microglia activation and a number of such new compounds

Country Status (31)

Country Link
EP (1) EP1246808B1 (el)
JP (1) JP2003523961A (el)
KR (1) KR100703908B1 (el)
CN (1) CN1301975C (el)
AT (1) ATE520669T1 (el)
AU (1) AU782993B2 (el)
BG (1) BG65858B1 (el)
BR (1) BR0107628A (el)
CA (1) CA2396227C (el)
CY (1) CY1112962T1 (el)
CZ (1) CZ303726B6 (el)
DK (1) DK1246808T3 (el)
EA (1) EA006302B1 (el)
EE (1) EE05515B1 (el)
ES (1) ES2372026T3 (el)
HR (1) HRP20020664B1 (el)
HU (1) HU228366B1 (el)
IL (2) IL150150A0 (el)
ME (1) MEP13308A (el)
MX (1) MXPA02005742A (el)
NO (1) NO326408B1 (el)
NZ (1) NZ519326A (el)
PL (1) PL209573B1 (el)
PT (1) PT1246808E (el)
RS (1) RS51860B (el)
SI (1) SI1246808T1 (el)
SK (1) SK287527B6 (el)
TW (1) TWI287005B (el)
UA (1) UA75589C2 (el)
WO (1) WO2001051473A1 (el)
ZA (1) ZA200206470B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
US6962932B2 (en) 2002-02-15 2005-11-08 Schering Aktiengesellschaft 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR101269869B1 (ko) 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
JP5255994B2 (ja) * 2008-11-04 2013-08-07 国立大学法人 岡山大学 核内受容体リガンド
WO2012012478A1 (en) 2010-07-21 2012-01-26 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
CN102382102B (zh) * 2010-09-06 2014-01-08 中国科学院广州生物医药与健康研究院 一种酰胺类化合物
EP2814486B8 (en) * 2012-02-17 2018-05-23 Kineta Viral Hemorrhagic Fever, LLC Antiviral drugs for treatment of arenavirus infection
WO2014044611A1 (en) 2012-09-20 2014-03-27 Bayer Pharma Aktiengesellschaft 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration
US10653669B2 (en) * 2015-12-15 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4430502A (en) * 1982-08-13 1984-02-07 The Upjohn Company Pyridinyl substituted benzimidazoles and quinoxalines
EP0520200B1 (en) * 1991-06-24 1998-02-18 Neurosearch A/S Imidazole compounds, their preparation and use
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
IL113472A0 (en) * 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
CA2248013A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis

Also Published As

Publication number Publication date
ATE520669T1 (de) 2011-09-15
HUP0204011A3 (en) 2003-07-28
CN1301975C (zh) 2007-02-28
NO20023362D0 (no) 2002-07-12
IL150150A (en) 2014-03-31
UA75589C2 (en) 2006-05-15
HU228366B1 (en) 2013-03-28
CZ303726B6 (cs) 2013-04-10
PL356091A1 (en) 2004-06-14
EA006302B1 (ru) 2005-10-27
AU782993B2 (en) 2005-09-15
BG106821A (bg) 2003-01-31
SK10002002A3 (sk) 2003-02-04
HRP20020664B1 (en) 2012-03-31
DK1246808T3 (da) 2011-12-05
YU45702A (sh) 2005-03-15
ZA200206470B (en) 2004-04-28
WO2001051473A1 (de) 2001-07-19
PL209573B1 (pl) 2011-09-30
NO326408B1 (no) 2008-12-01
WO2001051473A8 (de) 2002-01-03
BG65858B1 (bg) 2010-03-31
KR20020063629A (ko) 2002-08-03
TWI287005B (en) 2007-09-21
BR0107628A (pt) 2002-10-08
SK287527B6 (sk) 2011-01-04
CN1395568A (zh) 2003-02-05
SI1246808T1 (sl) 2011-12-30
PT1246808E (pt) 2011-11-30
RS51860B (sr) 2012-02-29
EA200200742A1 (ru) 2002-12-26
EE05515B1 (et) 2012-02-15
CA2396227A1 (en) 2001-07-19
KR100703908B1 (ko) 2007-04-05
CZ20022420A3 (cs) 2002-10-16
JP2003523961A (ja) 2003-08-12
ES2372026T3 (es) 2012-01-13
MEP13308A (en) 2010-10-10
EE200200390A (et) 2003-10-15
CA2396227C (en) 2012-03-20
HUP0204011A2 (en) 2003-05-28
AU4233201A (en) 2001-07-24
EP1246808B1 (de) 2011-08-17
CY1112962T1 (el) 2016-04-13
MXPA02005742A (es) 2002-09-18
HRP20020664A2 (en) 2005-04-30
NZ519326A (en) 2005-02-25
NO20023362L (no) 2002-09-13
EP1246808A1 (de) 2002-10-09

Similar Documents

Publication Publication Date Title
IL150150A0 (en) 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
MY133392A (en) Novel substituted pyrazole derivatives
HK1068262A1 (en) Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
NZ524742A (en) Bridged piperazine derivatives
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.
MY133107A (en) Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
SE0004101D0 (sv) New use
MXPA04001847A (es) Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
HK1044467A1 (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
TR200102009T2 (tr) Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
YU20902A (sh) Primena karbinola supstituisanih sa 2-imidazolilom za izradu medikamenta za lečenje ili profilaksu oboljenja izazvanih ishemičkim stanjima
IL160605A0 (en) Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
MXPA04001853A (es) Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad.
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
MXPA03003466A (es) Derivados de piranosido.